Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
Date:3/15/2011

clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking StatementsThis press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's ability to report data this quarter from both its OMS103HP Phase 3 ACL program and its Phase 2b ophthalmology trial of OMS302; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.OMEROS CORPORATION(A Development Stage Company)CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Grant revenue

$
976

$
434

$
2,105

$
,444Operating expenses:Research and development

6,947

4,638

23,465

16,929General and administrati
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... 7 Ardea,Biosciences, Inc. (Nasdaq: RDEA ) ... activity of the Company,s non-nucleoside reverse,transcriptase inhibitor (NNRTI) ... known causative agent of AIDS,including NNRTI-resistant strains., ... Conference on Retroviruses,and Opportunistic Infections (CROI) in Boston., ...
... gastrointestinal and lipid effects between ... N.J., Feb. 6 Bristol-Myers Squibb,Company (NYSE: ... study, in which,300 mg of once-daily REYATAZ(R) (atazanavir ... similar antiviral efficacy to twice-daily,lopinavir 400 mg and ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Thermage, Inc.,(Nasdaq: THRM ), announced today that ... and full year ended December 31, 2007, after the,market ... also host a,conference call and webcast on Tuesday, February ... to discuss the financial results and,current corporate developments. The ...
... The Bishop of Manchester,has made a series of serious ... researcher, inventor of the science of,Plastination, and creator of ... and at a Press Conference at Manchester Cathedral on ... WORLDS 4,exhibition, to be hosted by the Museum of ...
... It,s one thing to daydream about all,the free time ... to,seriously map out the steps you need to take ... Listen to this report from AXA Equitable (NYSE: ... access video, audio, text, graphics and,photos for free and ...
... study, a new technique helped patients retrieve long-lost details ... interviewing technique has drawn out extensive details hidden in ... researchers say. , There,s ongoing debate about whether long-term ... the medial temporal lobe, which contains the memory-processing center ...
... Record Annual Net Sales and Net Income, SALT LAKE ... a leading producer of advanced digital hearing aids,today announced results ... 2007 of $32.3 million were up 12.4% over the $28.7 ... year 2007 of $122.5,million improved 16.1% over the $105.5 million ...
... of $55.9 Million and Contract Value ... Growth of ... WASHINGTON, Feb. 5 The Advisory Board Company,(Nasdaq: ABCO ) ... March 31, 2008. Revenue for the quarter increased,15% to $55.9 million, from ...
Cached Medicine News:Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 2Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 3Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 4Health News:Brain Injury May Not Erase Long-Term Memory 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 3Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 4Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 5Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 6Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 7Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 2Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 3Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 4Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 5Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 6Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 7Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 8Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 9Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 10Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 12Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 13Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 14Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 15
Inquire...
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: